Scinai signs USD 5.1 million CDMO development, clinical manufacturing agreement

Bitget2026/10/13 11:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Scinai Immunotherapeutics signed a definitive development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company.
Contract includes about USD 5.1 million in committed base service fees, with revenue expected across 2026 and 2027.
Committed customer orders rose to about USD 7.6 million, up about 300% from USD 1.9 million at year-end 2025.
Additional clinical manufacturing could add an indicative, uncommitted USD 5.85 million in service fees for late 2027 to H1 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scinai Immunotherapeutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610130700PR_NEWS_USPR_____LN70008) on October 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Scinai signs USD 5.1 million CDMO development, clinical manufacturing agreement

You may also like

Crypto prices